Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
Conditions
Interventions
Intervention1: Methotrexate and folic acid once in a week and Prednisolone daily: 1st week: Methotrexate and folic acid 5mg, Prednisolone 40 mg.
2nd week: Methotrexate and folic acid 10mg, Prednisolon
Sponsors
Bankura Sammilani Medical College
Eligibility
Inclusion criteria
Inclusion criteria: Patients giving consent and clinically diagnosed cases of severe erythema nodosum leprosum value of ENLIST ENL severity scale is more than 8. Alcohol intake below national guideline. Patients unwilling to seek child birth and ready to follow at least 2 reliable contraceptive.
Exclusion criteria
Exclusion criteria: Pregnant and Lactating women. Patients with hypersensitivity to methotrexate or thalidomide or corticosteroid. Patients with contraindication to methotrexate or thalidomide or corticosteroid. Critically ill patients. Patients not on any of the following drugs: Immunosuppressant, pentoxifylline, chloroquine, colchicine or drugs known to interact with methotrexate or thalidomide or corticosteroid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of methotrexate and thalidomide towards onset of dose tapering and maintenance of discontinuation of systemic corticosteroid. Relapse rate of ENL treated with methotrexate and thalidomide. Timepoint: Weekly monitoring for total 48 weeks period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects of methotrexate and thalidomide. Net benefits of treatment using methotrexate and thalidomide for the patients.Timepoint: Weekly monitoring for total 48 weeks period. | — |
Countries
India
Contacts
Public ContactArghyaprasun Ghosh
Bankura Sammilani Medical College
Outcome results
None listed